• EE547 Budget Impact Analysis of Epcoritamab for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy in Greece

    Dec 1, 2024, 00:00

  • EE642 Cost-Effectiveness of Febuxostat 120/80 Mg as a Second-Line After Allopurinol 100/300MG in Gout Patients in Algeria

    Dec 1, 2024, 00:00

  • HPR178 Quantifying Health Inequity: An Umbrella Review of Systematic Literature Reviews on Sex-Based Differences in Health Outcomes

    Dec 1, 2024, 00:00

  • EPH17 Targeted Literature Review (TLR) on the Mortality in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) in the USA

    Dec 1, 2024, 00:00

  • PT32 Economic Evaluation of Abdominal Aortic Aneurysm Screening in the Czech Republic

    Dec 1, 2024, 00:00

  • HPR75 Development of a Conceptual Framework for Analyzing the Role of the Public Sector in the Development of New Valuable Health Innovations

    Dec 1, 2024, 00:00

  • EE829 Quantifying Disease-Specific Indirect Economic Burden Using Survey Research Methods as a Component of Estimating the Total Economic Burden of a Disease

    Dec 1, 2024, 00:00

  • EE521 Comparing the Cost-Effectiveness of a Novel Minimally Invasive Surgical Therapy for Benign Prostatic Hyperplasia (BPH): A Swedish Perspective

    Dec 1, 2024, 00:00

  • HTA104 Equity Is Not Equal: A Comparative Study of How Equity Is Considered by NICE, ICER, CDA-AMC, and PBAC

    Dec 1, 2024, 00:00

  • HSD61 One-Year Healthcare Utilization in People With Multiple Sclerosis and Controls in Wales

    Dec 1, 2024, 00:00

  • EE751 Direct Costs of RSV Cases (2022-2023 and 2023-2024 Seasons) in Hospitalized Patients and Out-Patients (Aged ≥60 Years) Prospectively Identified in Valladolid, Spain

    Dec 1, 2024, 00:00

  • EPH234 Estimation of Productivity-Adjusted Life Years (PALYs) and Condition-Specific PALY Loss Among the Late Middle-Aged Adults in China

    Dec 1, 2024, 00:00

  • EPH156 Estimated Public Health Impact of Italian Smokers Switching to Smoke-Free Products: A Population Health Impact Modeling Study

    Dec 1, 2024, 00:00

  • HPR65 Decision-Making in NICE, SMC, and NCPE: Assessing Time From Regulatory Approval to HTA Decision Outcome

    Dec 1, 2024, 00:00

  • CO31 Clinical Benefits of CDK 4/6 Inhibitors in HR+ HER2- Metastatic Breast Cancer: A Systematic Review

    Dec 1, 2024, 00:00

  • EPH38 Epidemiology, Prognosis, and Healthcare Resource Use of Patients With Pulmonary Hypertension Associated With Lung Disease and/or Hypoxia in the UK

    Dec 1, 2024, 00:00

  • EE391 Psychometric Performance of EQ-5D-5L and VILL-UI, a New Condition-Specific Preference-Weighted Measure, in Patients With Age-Related Macular Degeneration: A Macustar Study Report

    Dec 1, 2024, 00:00

  • EPH104 Assessment of the Associations Between Obesity and Obesity-Related Comorbidities

    Dec 1, 2024, 00:00

  • A Systematic Literature Review and Meta-Analysis of Primary Evidence Reporting Health-State Preference Values in Chronic Hepatitis B, C, and D

    Dec 1, 2024, 00:00

  • EE830 Exploring Long-Term Durability Assumptions in Cost-Effectiveness Models of Cell and Gene Therapies: A Study of 39 Health Technology Assessments

    Dec 1, 2024, 00:00

  • HTA206 For Orphan Drugs Technology Assessments, One Size May Not Fit All: Will the Implementation of JCA Lead to Increased Access or Will It Just Lead to a Duplication of Work?

    Dec 1, 2024, 00:00

  • EE828 Developing Automated Decision Rules Based on Vaccine Cost to Identify Optimal Vaccination Strategies

    Dec 1, 2024, 00:00

  • HTA78 Health Technology Assessment (HTA) Key Drivers for Oral Oncology Products: Comparison Between Brazil and European Countries

    Dec 1, 2024, 00:00

  • EE657 The Costs of Schizophrenia: A Systematic Review

    Dec 1, 2024, 00:00

  • EE286 Cost-Effectiveness of Nirmatrelvir/Ritonavir in Swedish Adults, Stratified by Age, Comorbidity and Vaccination Status, Compared to No Anti-Viral Treatment

    Dec 1, 2024, 00:00

  • HSD87 Evaluation of the Impact and Effectiveness of Support Services on the Use of Assistive Technologies

    Dec 1, 2024, 00:00

  • CO69 Indirect Treatment Comparison of Iptacopan Versus Eculizumab and Ravulizumab for Patients With Paroxysmal Nocturnal Hemoglobinuria Naive to C5 Inhibitors

    Dec 1, 2024, 00:00

  • EE537 A Cost-Benefit Analysis of Proton Therapy in Cancer Treatment: Enhancing Jordan's Medical Tourism

    Dec 1, 2024, 00:00

  • CO105 Impact of Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) Non-Persistence on Body Mass Index, HBA1C, and Lipids: Analysis of Over 190,000 Adults Treated With Semaglutide, Liraglutide, and Tirzepatide in US Real-World Data

    Dec 1, 2024, 00:00

  • EPH210 Landscape of Intrahepatic Cholangiocarcinoma (IHC) in Brazilian Public Healthcare System and Monitoring of the Technological Horizon

    Dec 1, 2024, 00:00

  • HTA198 Precedents for Reimbursed Highly Specialised Technologies Appraised By the National Institute for Health and Care Excellen Key Takeaways and Recommendations

    Dec 1, 2024, 00:00

  • EE600 Cost-Effectiveness and Budget Impact Analysis of Introducing Artificial Intelligence-Aided Colonoscopy for Adenoma Detection and Characterization in Spain

    Dec 1, 2024, 00:00

  • EE553 Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada

    Dec 1, 2024, 00:00

  • EE711 Cost Effectiveness of Intravenous Versus Oral Cytomegalovirus Treatment in Recipients of Allogeneic Hematopoietic Cell Transplant From Tunisian Hospital Perspective

    Dec 1, 2024, 00:00

  • Cover

    Dec 1, 2024, 00:00

  • HTA114 Characterizing Oncology Outcomes in Canada's Drug Agency (CDA-AMC) Reviews From 2022 -2023

    Dec 1, 2024, 00:00

  • EE624 Budget Impact of Intravenous Eptinezumab in the Prevention of Chronic Migraine Patients in United Arab Emirates

    Dec 1, 2024, 00:00

  • HSD131 Economic Evaluation of the Organizational Impact of Atezolizumab Subcutaneous in a French Hospital

    Dec 1, 2024, 00:00

  • EPH223 Trends in Epidemiology and Mortality of Patients With Melanoma in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • EE681 Healthcare Resource Utilization for Children Under 15 Years Old With Type 1 Diabetics : A Retrospective, Multicenter Analysis

    Dec 1, 2024, 00:00

  • CO60 Superior Cardiovascular Benefits of SGLT2 Inhibitors Over DPP4 Inhibitors for Severe Diabetic Kidney Disease: A Population-Based Cohort Study

    Dec 1, 2024, 00:00

  • EE509 Should Increase in Appropriate Self-Care Be Encouraged? Case Study on Economic Savings With Over-the-Counter (OTC) Ibuprofen in Dysmenorrhoea, Migraine, and Acute Rhinosinusitis in the UK

    Dec 1, 2024, 00:00

  • HTA147 The Butterfly Effect: Impact of EU HTA on Price Evolution Via International Reference Pricing

    Dec 1, 2024, 00:00

  • EE285 Conceptualization and Validation of a De Novo Cost-Effectiveness Analysis for Pulmonary Hypertension Associated With Interstitial Lung Disease

    Dec 1, 2024, 00:00

  • EE475 Cost-Benefit Analysis of Difficult Airway Management Techniques in Ukraine

    Dec 1, 2024, 00:00

  • HPR173 Literature Analysis of Artificial Intelligence Applications in Clinical Trial Design for Enhanced Efficiency and Patient Outcomes

    Dec 1, 2024, 00:00

  • HTA70 Insights into NICE's Approach to Uncertainties in Health Technology Appraisals

    Dec 1, 2024, 00:00

  • EE712 Economic and Clinical Impact of Immunization With Nirsevimab Among All Infants in Their First RSV Season Against Standard of Care in Japan

    Dec 1, 2024, 00:00

  • HPR82 Feasibility Study on the Possibilities for Implementation of National Screen Program for Lung Cancer in CEE Countries With Focus on the Balkan Region

    Dec 1, 2024, 00:00

  • HTA127 The Innovative Medicines Fund or the In Need of Medicines Fund: Analysis of NICE Technology Appraisals to Explore Barriers to Managed Access Agreements

    Dec 1, 2024, 00:00

  • EPH112 Prevalence and Costs of Potentially Inappropriate Medications for Elderly People Using Automated Multidose Dispensing Servi A Nationwide Register-Based Study

    Dec 1, 2024, 00:00

  • EE246 A Budget Impact Model Assessing Continuous Blood Glucose Monitoring Devices in Type 2 Diabetes Mellitus in Sweden

    Dec 1, 2024, 00:00

  • HSD113 Pilot Project for Implementing Value-Based Healthcare in Rheumatology for Inflammatory Arthritis Patients

    Dec 1, 2024, 00:00

  • HPR156 Understanding the Key Drivers, Barriers, and the Role of Different Socio-Economic Conditions When Vaccinating Against Invasive Meningococcal Serogroup B Disease in Europe: A Multi-Country Cross-Sectional Physician Survey

    Dec 1, 2024, 00:00

  • Methods for Measuring and Valuing Informal Care: A Systematic Review and Meta-Analysis in Stroke [Editor's Choice]

    Dec 1, 2024, 00:00

  • HSD111 Cost-Outcome Descriptive Analysis of an Internet Based Treatment for Depression, Social Anxiety, and Panic Disorder: A Post-Implementation Open Naturalistic Design Study

    Dec 1, 2024, 00:00

  • HTA19 Predicting Acceptability of Quantitative Evidence Synthesis for Joint Clinical Assessment Submissions: A Rating Scale

    Dec 1, 2024, 00:00

  • EE814 Potential Return on Subscription to a Smartphone Based Biometric Health Risk Assessment Tool

    Dec 1, 2024, 00:00

  • HTA214 Trends Underlying Positive and Negative Decision-Making for New Treatments Targeting Rare Diseases (RD) Appraised by the National Institute for Health and Care Excellence (NICE) in 2023

    Dec 1, 2024, 00:00

  • EE265 Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in Greece

    Dec 1, 2024, 00:00

  • HPR96 Price Monitoring of Anticancer Drugs Under Price Controlled Category in India

    Dec 1, 2024, 00:00

  • EE697 Cost-Effectiveness of Blood-Based Non-Invasive Testing Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Veteran Population

    Dec 1, 2024, 00:00

  • HTA17 NICE Early Value Assessment: A New Avenue for Evidence Generation and Early Market Access in the Digital Therapeutics Space in the United Kingdom

    Dec 1, 2024, 00:00

  • EE411 Budget Impact Analysis of Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease in Saudi Arabia: Analysis from Payer Perspective

    Dec 1, 2024, 00:00

  • HPR35 Influence of Pharmaceutical Competition on Compensable Price Differential (EMI): A Dynamic in Favor of Freely Negotiated Hospital Price?

    Dec 1, 2024, 00:00

  • HTA11 Early Access Programs (EAPs) in Fran Reasons for Refusal

    Dec 1, 2024, 00:00

  • EPH128 COVID-19 Is Here to Stay: Seasonal Endemic SARS-CoV-2 Infection Patterns Indicate Recurring Waves Adding to Respiratory and Cardiovascular Disease Burden in Germany

    Dec 1, 2024, 00:00

  • Editorial Board

    Nov 5, 2024, 08:49

  • Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe

    Nov 1, 2024, 00:00

  • Valuation of Multidimensional Health States With a Bolt-On: Is There a Shortcut? [Editor's Choice]

    Nov 1, 2024, 00:00

  • An Exploratory Study of Alternative Time Frames and Descriptors for EQ-5D-5L in Obstructive Airway Diseases Using Mixed Methods

    Nov 1, 2024, 00:00

  • Table of Contents

    Nov 1, 2024, 00:00

  • When Are You Recovered? Defining Cutoff Points Using the Acute Respiratory Tract Infection Questionnaire

    Nov 1, 2024, 00:00

  • How Many Monte Carlo Samples Are Needed for Probabilistic Cost-Effectiveness Analyses?

    Nov 1, 2024, 00:00

  • Choice Consistency in Discrete Choice Experiments: Does Numeracy Skill Matter?

    Nov 1, 2024, 00:00

  • Development of a Prioritization Framework to Aid Healthcare Funding Decision Making in Health Technology Assessment in Australia: Application of Multicriteria Decision Analysis

    Nov 1, 2024, 00:00

  • EQ-5D-5L Population Scores in Mainland China: Results From a Nationally Representative Survey 2021

    Nov 1, 2024, 00:00

  • Attribute Development in Health-Related Discrete Choice Experiments: A Systematic Review of Qualitative Methods and Techniques to Inform Quantitative Instruments [Editor's Choice]

    Nov 1, 2024, 00:00

  • Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task Force [Editor's Choice]

    Nov 1, 2024, 00:00

  • Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch

    Nov 1, 2024, 00:00

  • Clinical Outcome Assessments Are Never “Validated” [Editor's Choice]

    Nov 1, 2024, 00:00

  • Measuring Healthcare Experiences Among People With Intellectual Disability: A Rapid Evidence Synthesis of Tools and Methods

    Nov 1, 2024, 00:00

  • Assessing the Health and Welfare Benefits of Interventions Using the Wider Societal Impacts Framework [Editor's Choice]

    Nov 1, 2024, 00:00

  • Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey

    Nov 1, 2024, 00:00

  • First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis

    Nov 1, 2024, 00:00

  • The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers

    Nov 1, 2024, 00:00

  • Table of Contents

    Oct 1, 2024, 00:00

  • Do Behavioral Characteristics Influence the Breast Cancer Diagnosis Delay? Evidence From French Retrospective Data

    Oct 1, 2024, 00:00

  • Uncertainty in Long-Term Relative Effectiveness of Medicines in Health Technology Assessment [Editor's Choice]

    Oct 1, 2024, 00:00

  • Remote-Use Applications of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Clinical Outcome Assessment Tool: A Scoping Review

    Oct 1, 2024, 00:00

  • A New and Improved Experimental Design for the Discrete Choice Experiment Module of the EuroQol Valuation Technology Protocol

    Oct 1, 2024, 00:00

  • Patient-Reported Outcome Measures as an Intervention: A Comprehensive Overview of Systematic Reviews on the Effects of Feedback

    Oct 1, 2024, 00:00

  • Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands [Editor's Choice]

    Oct 1, 2024, 00:00

  • Author Reply

    Oct 1, 2024, 00:00

  • Mapping the Lequesne Functional Index Into the EQ-5D-5L Utility Index in Patients With Knee Osteoarthritis

    Oct 1, 2024, 00:00

  • Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Li ...

    Oct 1, 2024, 00:00

  • Generating Utilities for the Château-Santé Base: A Novel, Generic, and Patient-Centered Health-Outcome Measure

    Oct 1, 2024, 00:00

  • Traditional Methods Hold Their Ground Against Machine Learning in Predicting Potentially Inappropriate Medication Use in Older Adults [Editor's Choice]

    Oct 1, 2024, 00:00

  • Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program [Editor's Choice]

    Oct 1, 2024, 00:00

  • Author Reply

    Oct 1, 2024, 00:00

  • Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge

    Oct 1, 2024, 00:00

  • Cost-of/Burden-of-Illness Studies: Steps Backward?

    Oct 1, 2024, 00:00

  • A Tutorial on Value-Based Adaptive Designs: Could a Value-Based Sequential 2-Arm Design Have Created More Health Economic Value for the Big CACTUS Trial? [Editor's Choice]

    Oct 1, 2024, 00:00

  • Does Willingness to Pay Differ for Mental and Physical Health?

    Oct 1, 2024, 00:00

  • Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014

    Oct 1, 2024, 00:00

  • Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the European Union’s Regulation on Health Technology Assessment for Vaccines

    Oct 1, 2024, 00:00

  • Editorial Board

    Sep 27, 2024, 09:02

  • Further Evidence of Feasibility, Validity, and Reliability of Quality of Life-Aged Care Consumers: Evidence From Home-Based Care Settings

    Sep 1, 2024, 00:00

  • Facilitators and Barriers in the Implementation and Adoption of Patient-Reported Outcomes Measurements in Daily Practice

    Sep 1, 2024, 00:00

  • A Feasible Estimation of a “Corrected” EQ-5D Social Tariff

    Sep 1, 2024, 00:00

  • Experience Counts: Unveiling Patients’ Willingness to Pay for Remote Monitoring and Patient Self-Measurement

    Sep 1, 2024, 00:00

  • A Roadmap for Improving Medicare’s Application of Coverage With Evidence Development [Editor's Choice]

    Sep 1, 2024, 00:00

  • Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks [Editor's Choice]

    Sep 1, 2024, 00:00

  • Psychometric Performance of the EQ Health and Wellbeing Short in a United Kingdom Population Sample [Editor's Choice]

    Sep 1, 2024, 00:00

  • A Direct Comparison Between Discrete Choice With Duration and Composite Time Trade-Off Methods: Do They Produce Similar Results?

    Sep 1, 2024, 00:00

  • Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease

    Sep 1, 2024, 00:00

  • Table of Contents

    Sep 1, 2024, 00:00

  • Testing “Pits” Time Trade-Off: Can Data Quality be Improved by Removing Death From Valuation of Health States? [Editor's Choice]

    Sep 1, 2024, 00:00

  • Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI) [Editor's Choice]

    Sep 1, 2024, 00:00

  • A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best Practices

    Sep 1, 2024, 00:00

  • Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review

    Sep 1, 2024, 00:00

  • Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer

    Sep 1, 2024, 00:00

  • Putting a Dollar Value on Informal Care Time Provided to People Living With Dementia: A Discrete Choice Experiment

    Sep 1, 2024, 00:00

  • Editorial Board

    Aug 27, 2024, 14:04

  • Editorial Board

    Aug 7, 2024, 11:53

  • Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®)

    Aug 1, 2024, 00:00

  • It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties [Editor's Choice]

    Aug 1, 2024, 00:00

  • Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland

    Aug 1, 2024, 00:00

  • Table of Contents

    Aug 1, 2024, 00:00

  • The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States [Editor's Choice]

    Aug 1, 2024, 00:00

  • Can Generalized Cost-Effectiveness Analysis Leverage Meaningful Use of Novel Value Elements in Pharmacoeconomics to Inform Medicare Drug Price Negotiation?

    Aug 1, 2024, 00:00

  • Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review [Editor's Choice]

    Aug 1, 2024, 00:00

  • Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States

    Aug 1, 2024, 00:00

  • Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals [Editor's Choice]

    Aug 1, 2024, 00:00

  • The Long COVID Symptoms and Severity Score: Development, Validation, and Application

    Aug 1, 2024, 00:00

  • EQ-5D-5L Population Norms for China Derived From a National Health Survey

    Aug 1, 2024, 00:00

  • Navigating Public Policy Responses to a Pandemic: The Balancing Act Between Physical Health, Mental Health, and Household Income

    Aug 1, 2024, 00:00

  • Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma

    Aug 1, 2024, 00:00

  • How Do the Institute for Clinical and Economic Review’s Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee’s Assessments of Added Benefit? A Qualitative Study

    Aug 1, 2024, 00:00

  • Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019

    Aug 1, 2024, 00:00

  • A Systematic Review and Quality Assessment of Cardiovascular Disease-Specific Health-Related Quality-of-Life Instruments Part I: Instrument Development and Content Validity

    Aug 1, 2024, 00:00

  • Health Fluctuations in Dementia and its Impact on the Assessment of Health-Related Quality of Life Using the EQ-5D-5L [Editor's Choice]

    Aug 1, 2024, 00:00

  • Validating Health Economic Models With the Probabilistic Analysis Check dashBOARD

    Aug 1, 2024, 00:00

  • The Measurement Properties of the EQ-HWB and the EQ-HWB-S in Italian Population: A Comparative Study With EQ-5D-5L

    Jul 1, 2024, 00:00

  • Testing the Psychometric Properties of 9 Bolt-Ons for the EQ-5D-5L in a General Population Sample [Editor's Choice]

    Jul 1, 2024, 00:00

  • Understanding the Complex Interactions Between Interventions, Well-Being, and Resource Allocation

    Jul 1, 2024, 00:00

  • Challenges of Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: A Review of Methods and Modeling Suggestions

    Jul 1, 2024, 00:00

  • From Health to Well-Being: Toward a Monetary Valuation of a Well-Being-Adjusted Life-Year [Editor's Choice]

    Jul 1, 2024, 00:00

  • Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation

    Jul 1, 2024, 00:00

  • Values Beyond “Health” in Budget-Constrained Healthcare Systems [Editor's Choice]

    Jul 1, 2024, 00:00

  • The Ceiling Effects of EQ-5D-3L and 5L in General Population Health Surveys: A Systematic Review and Meta-Analysis

    Jul 1, 2024, 00:00

  • Cost-Effectiveness of 2 Models of Pessary Care for Pelvic Organ Prolapse: Findings From the TOPSY Randomized Controlled Trial

    Jul 1, 2024, 00:00

  • A Head-to-Head Comparison of EQ-HWB and EQ-5D-5L in Patients, Carers, and General Public in China

    Jul 1, 2024, 00:00

  • Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors

    Jul 1, 2024, 00:00

  • Construct Validity, Reliability, and Responsiveness of the 10-Item Well-Being Instrument for Use in Economic Evaluation Studies [Editor's Choice]

    Jul 1, 2024, 00:00

  • Table of Contents

    Jul 1, 2024, 00:00

  • Development of a Value Assessment Framework for Pediatric Health Technologies Using Multicriteria Decision Analysis: Expanding the Value Lens for Funding Decision Making

    Jul 1, 2024, 00:00

  • Editorial Board

    Jul 1, 2024, 00:00

  • Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study

    Jul 1, 2024, 00:00

  • Subjective Well-Being Population Norms and Inequalities in Hungary: A Large Cross-Sectional, Internet-Based Survey

    Jul 1, 2024, 00:00

  • Comparison of the EQ-HWB and EQ-HWB-S With Other Preference-Based Measures Among United States Informal Caregivers [Editor's Choice]

    Jul 1, 2024, 00:00

  • Social Decision-Making Analysis: A General Approach to Inform Decisions on Resources in the Public Sector [Editor's Choice]

    Jul 1, 2024, 00:00

  • Methods for Including Adverse Events in Economic Evaluations: Suggestions for Improvement

    Jul 1, 2024, 00:00

  • Anti–Vascular Endothelial Growth Factor Drugs Compared With Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A Cost-Effectiveness Analysis

    Jul 1, 2024, 00:00

  • Editorial Board

    Jun 12, 2024, 08:53

  • EE293 A Framework to Assess Uncertainties of Polygenic Risk Scores in Disease Screening and Prevention in Cost-Effectiveness Analyses

    Jun 1, 2024, 00:00

  • HSD121 Real-World Prescribing of Tirzepatide Labeled for Obesity in the United States

    Jun 1, 2024, 00:00

  • PCR165 Health-Related Quality of Life of Type 1 Diabetes and Severe Hypoglycemia in Adult Continuous Glucose Monitor Users: Results From a Cross-Sectional Survey in the United States

    Jun 1, 2024, 00:00

  • RWD166 Evaluation of the One-Day Surgical Performance of the Hungarian Universities in the Obstetrics and Gynecology Medical Field

    Jun 1, 2024, 00:00

  • HTA6 Use of Medical Device Assessment Criteria in CONITEC Evaluations

    Jun 1, 2024, 00:00

  • EPH213 Burden of Heart Failure After Hospitalization for Myocardial Infarction in the United States: A Targeted Literature Review

    Jun 1, 2024, 00:00

  • HTA34 Cost-Effectiveness Analysis of Icosapent Ethyl (IPE) for the Reduction of the Severe Hypertriglyceridemia (HTG) in China

    Jun 1, 2024, 00:00

  • EE19 Cost-Effectiveness Analysis of Infliximab, Adalimumab, and Certolizumab for Crohn's Disease: A Markov Model Study

    Jun 1, 2024, 00:00

  • EE485 Cost-Effectiveness of Active Surveillance for Incidentally Detected Early-Staged Papillary Thyroid Cancer: A Microsimulation Study

    Jun 1, 2024, 00:00

  • PCR188 Compliance and Design Features of Electronic Participant-Reported Dosing Diaries

    Jun 1, 2024, 00:00

  • Patient-Centered Research

    Jun 1, 2024, 00:00

  • PCR196 Psychometric Validation of the PROMIS Fatigue-Short Form 7A in Adults with Newly Diagnosed or Recurrent Mycobacterium avium Complex (MAC) Lung Disease: The ARISE and ENCORE Studies

    Jun 1, 2024, 00:00

  • EPH108 Clopidogrel Resistance in Patients With Recurrent Ischaemic Stroke on Dual Antiplatelet Therapy and Its Economic Impact in a Lower-Middle Income Country: A Single Centered Study in Southern India

    Jun 1, 2024, 00:00

  • SA24 CHIME2 (Chinese Hong Kong Integrated Modeling and Evaluation): An Updated Model to Simulate Lifetime Health Outcomes of Patients with Type 2 Diabetes

    Jun 1, 2024, 00:00

  • RWD192 Real-World Use of Tirzepatide Among People Without Evidence of Type 2 Diabetes: Results From Merative Marketscan Commercial Database

    Jun 1, 2024, 00:00

  • SA28 Using Linked Claims-EHR Data: The Added Value When Assessing Comorbidity Burden Among Patients With Asthma

    Jun 1, 2024, 00:00

  • MT15 Postoperative Clinical and Economic Outcomes of Patients With Reverse or Anatomic Total Shoulder Arthroplasty at One Year: A Retrospective, United States Hospital Billing Database Analysis

    Jun 1, 2024, 00:00

  • EE353 An Analysis of Stakeholders’ Contribution to High-WAC and Low-WAC Adalimumab Products in 2025 Under the Inflation Reduction Act in the United States

    Jun 1, 2024, 00:00

  • CO91 Systemic Therapy Eligibility Criteria of the International Psoriasis Council (IPC) May Reduce Undertreatment of PsO Patients with Low Body Surface Area Involvement Associated with High Disease Burden

    Jun 1, 2024, 00:00

  • MSR9 Can Artificial Intelligence Tools Enhance Data Abstraction During Systematic Literature Reviews?

    Jun 1, 2024, 00:00

  • CO70 Comparative Bayesian Network Meta-Analysis of BTKi-Specific Adverse Events in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

    Jun 1, 2024, 00:00

  • P7 Costs and Health Care Resource Utilization Associated with Negative Symptoms Among Patients with Schizophrenia in the United States

    Jun 1, 2024, 00:00

  • CO26 Targeted Literature Review Exploring Burden of Disease in Junctional and Dystrophic Epidermolysis Bullosa

    Jun 1, 2024, 00:00

  • EPH226 Associations between Antimicrobial Susceptibility of Streptococcus Pneumoniae and Disease Severity Outcomes in Older Adults with Invasive Pneumococcal Disease in Sao Paulo, Brazil

    Jun 1, 2024, 00:00

  • HSD1 Assessing Community Pharmacist Expectation, Satisfaction, and Intentions in the Wasfaty E-Servi Using the Expectation Conformation Theory

    Jun 1, 2024, 00:00

  • RWD157 Objective Fit-4-Purpose Assessment of Real-World Data for Evidence Generation in Type 2 Diabetes Mellitus: A Trial Tokenization Approach

    Jun 1, 2024, 00:00

  • HTA11 Manufacturer Engagement and Revision Outcomes in the “Phase Contradictoire” of the HTA Process in Fran A Descriptive Analysis

    Jun 1, 2024, 00:00

  • RWD158 Assessing RSV Vaccination Trends in the Context of Seasonal RSV Diagnoses Using Near Real-Time Administrative Claims

    Jun 1, 2024, 00:00

  • RWD3 Review of the Use of Electronic Health Records for Advancing Schizophrenia Research in the UK

    Jun 1, 2024, 00:00

  • Advancing the Use of Patient Reported Outcomes

    Jun 1, 2024, 00:00

  • EPH132 Adverse Drug Reaction-Related Hospital Admission in Older Australians With Dementia

    Jun 1, 2024, 00:00

  • HPR100 Health Technologies Value Assessment Through the Lens of Health Equity; How Far From Being Incorporated Routinely? An Environmental Scan of Health Equity Frameworks and Policy Gaps

    Jun 1, 2024, 00:00

  • MT36 Assessment and Comparison of the Manual Steps Required to Perform Whole Blood Processing Using a Semi-Automated Method Versus a Fully Automated Method

    Jun 1, 2024, 00:00

  • EPH147 Socioeconomic Burden of Ischemic Heart Diseases in the Japanese Healthcare System – A System Dynamics Simulation for Policy Decision-Making

    Jun 1, 2024, 00:00

  • EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists

    Jun 1, 2024, 00:00

  • EE510 Navigating Economics of Telehealth in Oncology

    Jun 1, 2024, 00:00

  • MSR58 Comparing Predictive Models: Traditional Versus Modern Statistical Approaches for Economic Outcomes in Major Depressive Disorder

    Jun 1, 2024, 00:00

  • HTA28 Comparative Analysis of Orphan Drug HTA Assessment: Perspectives from HAS and SMC

    Jun 1, 2024, 00:00

  • EE288 Decision Model to Evaluate the Cost of Clinical Events Associated with Switching from Apixaban to Rivaroxaban Among Patients with Non-Valvular Atrial Fibrillation in Germany

    Jun 1, 2024, 00:00

  • EPH183 The Association Between the Minority Health Social Vulnerability Index and Pneumococcal Disease Incidence Among Medicare Beneficiaries (2016-2019)

    Jun 1, 2024, 00:00

  • RWD183 Experience in Implementing Clinical Trial to Real-World Data (RWD) Linkage

    Jun 1, 2024, 00:00

  • MSR35 Item Performance and Structural Validity of the Quick Motor Function Test Among Late Onset Pompe Disease Patients

    Jun 1, 2024, 00:00

  • EE132 Economic Outcomes and Real-World Adherence of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises Treated With L-Glutamine, Voxelotor, and Crizanlizumab in the United States

    Jun 1, 2024, 00:00

  • PT44 Prevalence of Comorbidities and Hospitalization in the 65 and over SLE (SYSTEMIC LUPUS ERYTHEMATOSUS) Patient Population: A Comparative Analysis of the FORWARD Lupus Registry and Medicare Data in the US (2017-2021)

    Jun 1, 2024, 00:00

  • EE164 A Systematic Review and Meta-Analysis of Economic Burden of Breast Cancer Among Adult Females: Based on the Perspective of Social Development Level and Progression of Disease

    Jun 1, 2024, 00:00

  • RWD96 Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Rheumatoid Arthritis: A Systematic Review

    Jun 1, 2024, 00:00

  • HSD16 Understanding Causes and Consequences in the Operating Room Associated with Distractions, Interruptions, and Disruptions: A Focused Literature Review

    Jun 1, 2024, 00:00

  • RWD54 Comparative Analysis of Different Methods of Disease Progression Data Capture in Patients With Metastatic Castration-Resistant Prostate Cancer

    Jun 1, 2024, 00:00

  • EE333 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the U.S.: An Updated Analysis

    Jun 1, 2024, 00:00

  • EE369 Healthcare Resource Utilization Among Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada

    Jun 1, 2024, 00:00

  • EE151 Clinical and Economic Benefits of Adjuvanted and High-Dose Influenza Vaccines in the Elderly in Argentina

    Jun 1, 2024, 00:00

  • PCR62 Household Costs for Home, Vehicle, and Medical Equipment Expenditures to Accommodate Functional Impairments for Individuals with Duchenne Muscular Dystrophy

    Jun 1, 2024, 00:00

  • CO115 Long-Term Post-Recurrence Survival (PRS) Outcomes for Stage IIB/C Melanoma Patients in Real-World (RW) Settings: Analyses from a Longitudinal Electronic Health Record Database in the United States

    Jun 1, 2024, 00:00

  • CO81 Cyclosporine Ophthalmic Solution 0.09% Improves the Signs and Symptoms of Dry Eye Disease in Patients Whose Disease Is Inadequately Controlled on Cyclosporine Ophthalmic Emulsion 0.05%

    Jun 1, 2024, 00:00

  • Psychometric Properties of the EQ-5D-Y-5L for Children With Intellectual Disability

    Jun 1, 2024, 00:00

  • EPH107 Characteristics of the COVID-19 Epidemic in Three Hungarian Disctricts

    Jun 1, 2024, 00:00

  • EE307 Economic Evaluation of a Screening Programme for Diabetes, Hypertension and Hyperlipidaemia in Middle-Aged Adults in Hong Kong: A Simulation Analysis

    Jun 1, 2024, 00:00

  • Clinical Outcomes

    Jun 1, 2024, 00:00

  • HPR96 Racial Disparity and Awareness of Disease-Risk Genetic Testing: A Nationwide Sampling Survey Analysis

    Jun 1, 2024, 00:00

  • HSD51 Evaluation of the Healthcare System Burden Associated With Intravenous Treatment for Paroxysmal Nocturnal Hemoglobinuria

    Jun 1, 2024, 00:00

  • PCR103 Young People’s Preferences Towards Web-Based Mental Health Interventions for Anxiety and Depression: A Discrete Choice Experiment

    Jun 1, 2024, 00:00

  • PCR81 Association between Video Gaming Habits and Psychological Distress Among Adolescents

    Jun 1, 2024, 00:00

  • EPH73 Clinical Characteristics of Patients in the Intensive Care Unit with Infections Caused By Multiresistant Gram-Negative Bacteria

    Jun 1, 2024, 00:00

  • MT23 The Changing Healthcare Landscape of Lumbar Spinal Fusion: Two-Year Claims Database Analysis

    Jun 1, 2024, 00:00

  • CO42 Disease Burden of Anal Carcinoma in Chinese Male Patients Under Current Care: A Model Simulation Study

    Jun 1, 2024, 00:00

  • HPR89 Trends in Hospital Charging Practices from 2019-2022 Among Hospitals with and without Chimeric Antigen Receptor (CAR) T-Cell Therapy Utilization

    Jun 1, 2024, 00:00

  • RWD97 Real-World Disease Burden of Fibrodysplasia Ossificans Progressiva in China

    Jun 1, 2024, 00:00

  • RWD146 Characterization of Chronic Kidney Disease Patients By eGFR Status Using Health Insurance Claims Linked to Lab Testing Data

    Jun 1, 2024, 00:00

  • PCR5 Perceptions, Experiences, and Behaviors of Patients and Their Caregivers With Gastric and Gastroesophageal Cancer Treated With or Without Trastuzumab Deruxtecan (T-DXd) in the United States

    Jun 1, 2024, 00:00

  • CO137 Are Standard Indirect Treatment Comparison Methods Suitable to Compare First-Line Vs Maintenance Therapies? An Assessment of Enfortumab Vedotin + Pembrolizumab Vs Avelumab in Locally Advanced/Metastatic Urothelial Carcinoma

    Jun 1, 2024, 00:00

  • EE76 Anterior-Based Muscle-Sparing Approach (ABLE) Is Cost-Effective When Compared with Posterolateral and Direct Anterior Approaches for Total Hip Arthroplasties

    Jun 1, 2024, 00:00

  • HSD45 Effectiveness of Aseptic and Disinfection Measures in Dental Offices in Barranquilla, Colombia

    Jun 1, 2024, 00:00

  • HSD106 Metastatic Colorectal Cancer (mCRC) Patients Treated with Later Lines of Treatment (LOT): A Retrospective Analysis By Race and Ethnicity in the United States (US) Community Oncology Setting

    Jun 1, 2024, 00:00

  • PCR64 Examining the Disability Paradox and Health State Utility Valuation in Achondroplasia

    Jun 1, 2024, 00:00

  • PCR258 Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder Among Adults in the United States

    Jun 1, 2024, 00:00

  • EE501 Estimating the Impact of Delayed Treatment for Major Depressive Disorder Using a Continuous-Time Patient-Level Simulation Model

    Jun 1, 2024, 00:00

  • EPH19 Opioid-Related Overdose Death Rates in the US From 2005 to 2021

    Jun 1, 2024, 00:00

  • PCR48 Health-Related Quality of Life for Disease-Modifying Therapies Among Patients With Spinal Muscular Atrophy in Taiwan

    Jun 1, 2024, 00:00

  • HPR88 Variation in State Medicaid Use of Brand-over-Generic Preferred Drug Lists

    Jun 1, 2024, 00:00

  • SA68 Assessment of Real-World Data Sources and a Hybrid Approach in Real-World Evidence Generation Using Unharmonized Data Sources

    Jun 1, 2024, 00:00

  • PCR199 Advancing Patient-Centered Outcomes Research for Rare Diseases: A Mixed-Methods Approach

    Jun 1, 2024, 00:00

  • EE463 A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Vs Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate or Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Peru

    Jun 1, 2024, 00:00

  • EE182 Mepolizumab Impact on Healthcare Resource Utilization and Work Productivity in Patients with Severe Asthma: REALITI-A 2-Year Analysis

    Jun 1, 2024, 00:00

  • MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare

    Jun 1, 2024, 00:00

  • PT20 Gleaning Novel Insights from Real World Data: A Machine-Learning Guided Analytical Framework

    Jun 1, 2024, 00:00

  • CO50 Benefit and Risk of Oral Anticoagulant Initiation Strategies in Patients With Atrial Fibrillation and Cancer: A Target Trial Emulation Using the SEER-Medicare Database

    Jun 1, 2024, 00:00

  • EE128 Customer Service Analytics Improve Health Outcomes at Blue Cross and Blue Shield of Louisiana

    Jun 1, 2024, 00:00

  • EE274 Cost-Effectiveness Analysis of Large-Scale Screening for Celiac Disease in the Pediatric Population

    Jun 1, 2024, 00:00

  • HTA76 Insights into Health Technology Reassessment in Fran A Comprehensive Analysis of Key Outcomes and Manufacturers Engagement (2022-2023)

    Jun 1, 2024, 00:00

  • MSR14 Multi-Output Learning for Rare Event Analysis

    Jun 1, 2024, 00:00

  • EPH153 Screening Interval for Colonoscopic Screening for Colorectal Cancer: A Systematic Review of Interval Cancer Rates of Colonoscopic Screening for Colorectal Cancer

    Jun 1, 2024, 00:00

  • PCR209 Joint Modeling of Progression-Free Survival (PFS) and Patient-Reported Symptoms Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients

    Jun 1, 2024, 00:00

  • MSR52 Assessing the Representativeness of Provider Encounter Data From a Large Claims Database on Adults With Major Depression

    Jun 1, 2024, 00:00

  • HPR125 Novel Drug Approvals By the U.S. Food and Drug Administration in Rare Diseases: Findings from 2020–2023

    Jun 1, 2024, 00:00

  • EPH127 Association of Marijuana Use With Poor Mental Health Among Non-Institutionalized Adults in the US

    Jun 1, 2024, 00:00

  • EE8 Targeted Literature Review for Estimating Median Age of Causal Human Papilloma Virus Infection to Oropharyngeal Cancer

    Jun 1, 2024, 00:00

  • HSD31 Analyzing Factors Affecting Length of Emergency Department Stay in Patients With Hemophilia

    Jun 1, 2024, 00:00

  • PCR50 Estimating Meaningful Change Thresholds (MCTs) for EORTC Scales in a Phase 3 Trial in Participants With Inoperable or Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

    Jun 1, 2024, 00:00

  • MT42 Evaluation of a Novel Single-Use Ureteroscope: User Satisfaction Comparison Survey

    Jun 1, 2024, 00:00

  • HTA18 Heading into the Unknown: How Will JCA Implementation Affect Global Launch Strategies?

    Jun 1, 2024, 00:00

  • CO180 Newer Glucose-Lowering Drugs and Risk of Depression: A Meta-Analysis of Randomized Outcome Trials

    Jun 1, 2024, 00:00

  • RWD53 An Inflection Point in Real-World Treatment Intensification for Men With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the United States (US): Results From Patient Chart Reviews

    Jun 1, 2024, 00:00

  • CO200 Gender Differences in Clinician-Recorded Side Effects Among People With First Episode Psychosis: Real-World Evidence From Electronic Health Record Data

    Jun 1, 2024, 00:00

  • PCR66 Improving Quality of Life in Endometriosis Patients: A Study on Lifestyle and Pain Scores

    Jun 1, 2024, 00:00

  • HTA27 An Analysis of Manufacturer and Patient Engagement with Institute for Clinical and Economic Review Assessments

    Jun 1, 2024, 00:00

  • HPR129 Real-World Policy Effects of Implementing Multi-Gene Panel Sequencing for Advanced Cancers in British Columbia, Canada: An Interrupted Time Series Analysis

    Jun 1, 2024, 00:00

  • HPR80 Moving Towards Inclusion: A Review of Access to Oncologic Therapies in the Light of Global Efforts to Advance Gender Equality

    Jun 1, 2024, 00:00

  • EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective

    Jun 1, 2024, 00:00

  • HPR141 Model Analysis on Budget Impact and Patients’ Burden of National Price-Negotiated Drugs and Different Reimbursement Payment Modes in China: Hyperkalemia As an Example

    Jun 1, 2024, 00:00

  • CO3 Prediction of Long-Term Factor IX Durability Among Hemophilia B Patients Treated with Fidanacogene Elaparvovec Gene Therapy

    Jun 1, 2024, 00:00

  • HPR111 Disease Burden and Medical Insurance Expenditure of National Price-Negotiated Drugs for Multiple Sclerosis Under Dual-Channel Model in China: A Budget Impact Model

    Jun 1, 2024, 00:00

  • CO141 Situation Report: Health Status of Hungarian Ambulance Workers in the COVID Era

    Jun 1, 2024, 00:00

  • EE87 Time-Driven Activity Based Costing of Advanced Ovarian Cancer From the Perspective of a Brazilian Public Hospital

    Jun 1, 2024, 00:00

  • P60 Evaluating Dynamic Treatment Using a Target Trial: The Real-World Effectiveness of Adding Oral Selexipag to a Double Oral Therapy for the Treatment of Patients With Pulmonary Arterial Hypertension

    Jun 1, 2024, 00:00

  • SA2 A Unique Approach for Identifying Thoracic Endovascular Aortic Repair Stent Graft Landing Zones 0/1/2 Using Revascularization Procedure Codes from a Commercial Claims Database

    Jun 1, 2024, 00:00

  • HPR105 Breadth of Patient and Stakeholder Input in CMS's Drug Price Negotiation Program: A Content Analysis of the 2023 Patient-Focused Listening Sessions

    Jun 1, 2024, 00:00

  • CO13 A Claims Analysis To Characterize All-Cause Mortality in Patients With Generalized Pustular Psoriasis in the United States

    Jun 1, 2024, 00:00

  • CO146 Treatment Use and Overall Survival of Patients with Unresectable/Metastatic Melanoma in Colombia: A Real World Study

    Jun 1, 2024, 00:00

  • EE148 The Institutional Level Impact of Additional Apheresis Days for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation on Costs and Healthcare Resource Utilization

    Jun 1, 2024, 00:00

  • CO160 Relationship between Loss of Ambulation (LoA), Disease Burden, and Physical Functioning Among Boys with Duchenne Muscular Dystrophy (DMD)

    Jun 1, 2024, 00:00

  • EE528 Comparative Effectiveness Modeling of an Anti-Pd-1 Antibody Drug Intervention for Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the U.S.

    Jun 1, 2024, 00:00

  • EE514 Private Hospital Acute Stroke Care Costs: Patient's Viewpoint

    Jun 1, 2024, 00:00

  • RWD87 Real-World Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization in Patients in the US With Metastatic Non-Small Cell Lung Cancer Receiving Systemic Anticancer Therapy

    Jun 1, 2024, 00:00

  • MSR53 Estimands in EQ-5D-5L: How to Deal with the “Worse Than Death” and the Intercurrent Events of “Death”

    Jun 1, 2024, 00:00

  • CO41 Comparative Effectiveness of Glucagon-like Peptide 1 Agonists Vs Dipeptidyl Peptidase 4 Inhibitors on Liver Outcomes in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease

    Jun 1, 2024, 00:00

  • EPH149 Regional Dynamics and Prevalence of COVID-19 Variants in US Health and Human Services Regions

    Jun 1, 2024, 00:00

  • HPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision Updates

    Jun 1, 2024, 00:00

  • HTA63 The Role and Implementation of Patient and Public Involvement in Health Technology Assessment: A Systematic Search and Implications for Japan

    Jun 1, 2024, 00:00

  • PCR49 Mapping and Linking between the EQ-5D-5L and the PROPr in the United States

    Jun 1, 2024, 00:00

  • MSR83 Predicting Optimal Treatment Regimen to Improve Outcomes of Patients With CLL/SLL Using Random Survival Forest

    Jun 1, 2024, 00:00

  • EE252 Economic Impact of Relapses in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A Systematic Literature Review

    Jun 1, 2024, 00:00

  • MSR57 Transforming Systematic Literature Reviews: Unleashing the Potential of GPT-4: A Cutting-Edge Large Language Model, to Elevate Research Synthesis

    Jun 1, 2024, 00:00

  • HPR77 CMS Coverage Lift on PET Beta Amyloid Imaging Impact on mAb Treatment and Beneficiary Out-Of-Pocket Spending

    Jun 1, 2024, 00:00

  • SA72 Health System As an Adaptative Complex System for Open Innovation

    Jun 1, 2024, 00:00

  • EE250 Work Productivity Loss Among Adults Aged 18–64 Years With Osteoarthritis in the United States: 2016-2020

    Jun 1, 2024, 00:00

  • CO108 The Effect of Approved Anti-Obesity Medications in Patients With Alcohol and Substance Abuse Disorder

    Jun 1, 2024, 00:00

  • MSR18 Improving the Performance of Generative AI to Achieve 100% Accuracy in Data Extraction

    Jun 1, 2024, 00:00

  • CO8 Leading Predictors of Incident Hypertension Among Patients with Cancer in Community Health Centers: A Machine Learning Approach with Shapley Additive Explanations Using Electronic Health Records

    Jun 1, 2024, 00:00

  • EPH130 Mortality Related with Respiratory Syncytial Virus (RSV) Specific and Unspecified Acute Bronchiolitis in Under 2 Years in Colombia, 2012-2021

    Jun 1, 2024, 00:00

  • PCR192 Using Linked Claims and EHR Real-World Data to Determine Medication Adherence Among Common Therapeutic Areas of Chronic Disease

    Jun 1, 2024, 00:00

  • MSR36 Current Applications of Machine Learning for Causal Inference in Healthcare Research Using Observational Data

    Jun 1, 2024, 00:00

  • EPH8 Comparison of Patient Identification Methodologies in Chronic Inflammatory Demyelinating Polyneuropathy Using United States Administrative Claims Data

    Jun 1, 2024, 00:00

  • MT47 Navigating the Roadblocks: Identifying the Complexities and Challenges of Artificial Pancreas in Management of Type 1 Diabetes Mellitus

    Jun 1, 2024, 00:00

  • EE387 Healthcare Resource Utilization for Patients With Alzheimer's Disease Versus Non-Alzheimer's Disease Controls in Israel

    Jun 1, 2024, 00:00

  • PCR228 Healthcare Provider Preferences for Attributes of Influenza Vaccines in the United States: Results From a Discrete-Choice Experiment Study

    Jun 1, 2024, 00:00

  • SA39 Exploring the Landscape of Genetically Modified Natural Killer Cell (GMNKC) Therapies: A Review of Clinical Trials Indexed on ClinicalTrials.gov

    Jun 1, 2024, 00:00

  • EE437 Evaluating Various Predictors Suspected of Influencing Biosimilar Market Share in the U.S.

    Jun 1, 2024, 00:00

  • SA54 Expanding the Horizon of Cost-Effectiveness Analysis: A Comprehensive Review of Alternative Methods

    Jun 1, 2024, 00:00

  • HSD113 Treatment Patterns, Comorbidities, Healthcare Resource Utilization and Related Costs of Dermatomyositis and Polymyositis in the United States: A Cohort Study in the Merative™ MarketScan® Database

    Jun 1, 2024, 00:00

  • EPH176 Comparison of Superoxide Dismutase Activities (Mn-SOD AND Cu/Zn-SOD) in Patients Infected with Dengue Virus or Zika Virus

    Jun 1, 2024, 00:00

  • Real-World Data Information Systems

    Jun 1, 2024, 00:00

  • EE118 Impact of Different Thresholds on Recommendations Made Through Cost-Effectiveness Studies: An Example From Chronic Lymphocytic Leukemia

    Jun 1, 2024, 00:00

  • HTA75 Utilization of Artificial Intelligence By Health Technology Assessment Agencies to Improve Efficiency of Health Technology Appraisals

    Jun 1, 2024, 00:00

  • HPR91 Public Sector Replacement of Privately Funded Pharmaceutical RD: Cost and Efficiency Considerations

    Jun 1, 2024, 00:00

  • RWD165 Burden of Illness of Intrauterine Adhesions Following Intrauterine Procedures: A Retrospective Analysis of Real-World Data

    Jun 1, 2024, 00:00

  • EE505 Predictive Analysis Comparing Economic and Clinical Consequences of Treatment-related Hepatotoxicity in KRASG12C-mutated Advanced Non-small Cell Lung Cancer (aNSCLC) Patients Treated Post-immunotherapy (IO)

    Jun 1, 2024, 00:00

  • PCR52 Early Real-World Experience With Abrilada Within the Canadian Patient Population

    Jun 1, 2024, 00:00

  • HSD99 Impact of Pink October in Mammographic Screening in a Health Care Plan in Brazil

    Jun 1, 2024, 00:00

  • HPR54 The European Health Data Space (EHDS): Probable Impact, Possible Challenges and Proposed Solutions to Using Electronic Health Records (EHRS) for Research and Policy Shaping in the Region

    Jun 1, 2024, 00:00

  • HPR123 Impact of Mandated Use of the Texas Prescription Monitorsing Program on Carisoprodol Dispensing in Texas

    Jun 1, 2024, 00:00

  • EE289 Cost-Effectiveness Analysis of Blinatumomab for Advanced Acute Lymphoblastic Leukemia in Japan

    Jun 1, 2024, 00:00

  • SA7 Outcomes With Novel Therapies for Relapsed or Refractory Follicular Lymphoma: A Targeted Literature Review

    Jun 1, 2024, 00:00

  • RWD23 Development of an Optimal Corticosteroid Dosage Regimen for the Management of Acute Respiratory Distress Syndrome: A Sequential Explanatory Mixed Method Approach

    Jun 1, 2024, 00:00

  • RWD5 A Novel Predictive Model for Agitation in Alzheimer’s Dementia Using Administrative Claims Data

    Jun 1, 2024, 00:00

  • Addressing Confounding in Real-World Evidence Studies

    Jun 1, 2024, 00:00

  • EE328 Direct Medical Costs in Patients with Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) in Colombia

    Jun 1, 2024, 00:00

  • RWD70 Dental Complication Burden in Patients with Phosphorus Metabolism and Phosphatase Disorders: Insights from a 14-Year Nationwide Longitudinal Retrospective Study in South Korea

    Jun 1, 2024, 00:00

  • EE16 Economic Analysis of the Impact of Delandistrogene Moxeparvovec Gene Therapy on Work Opportunity in Caregivers of Individuals with Duchenne Muscular Dystrophy

    Jun 1, 2024, 00:00

  • MT26 HTA Requirements for Medical Technologies in Canada

    Jun 1, 2024, 00:00

  • CO206 The Clinical and Financial Impact of Sustained Annual Wellness Visit Engagement in the Blue Cross and Blue Shield of Louisiana Medicare Advantage Population

    Jun 1, 2024, 00:00

  • P64 Which Healthcare-System Factors Influence Reimbursement Success Rates? A Multi-Country Analysis of Reimbursement Decisions in 2023

    Jun 1, 2024, 00:00

  • EPH10 Serotype Distribution Among Streptococcus Pneumoniae Isolates in Puerto Rico (PNEUMOSER STUDY)

    Jun 1, 2024, 00:00

  • RWD86 Impact of Population Aging on the Colombian Health System: A Real-World Data Analysis

    Jun 1, 2024, 00:00

  • EE153 Cost-Minimization of Oral Valganciclovir Vs Intravenous Ganciclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients

    Jun 1, 2024, 00:00

  • HPR58 Mapping Medicaid: A Comparative Analysis of State-Level Racial and Ethnic Data Collection to Federal Guidelines

    Jun 1, 2024, 00:00

  • EE457 Economic Burden Impact of Thyroid Eye Disease in the United Arab Emirates

    Jun 1, 2024, 00:00

  • HSD73 Neoadjuvant Adjuvant Therapy for Early-Stage/Resectable Non-Small Cell Lung Cancer (NSCLC): Physician Practices, Therapy Choice, and Challenges Among US Oncologists

    Jun 1, 2024, 00:00

  • MSR61 Perceptions of the Feasibility of AI-Based Machine Translation for Linguistic Validation

    Jun 1, 2024, 00:00

  • PCR46 A Qualitative Exploration of Patient and Healthcare Provider Perspectives on Oxybate Treatments for Narcolepsy

    Jun 1, 2024, 00:00

  • MSR3 Cough, Dyspnea, Chest Pain or a Composite? Analysis of Key Symptoms in Metastatic Non-Small Cell Lung Cancer (mNSCLC) Clinical Trials

    Jun 1, 2024, 00:00

  • P40 Caregivers’ Stated and Revealed Preferences for Antipsychotic Medication Use Among Youth: A Discrete Choice Experiment of Benefit-Risk Trade-Offs

    Jun 1, 2024, 00:00

  • EPH119 Public Health Results in the Department of Bolívar, Colombia: An Analysis of Indicators in 2023

    Jun 1, 2024, 00:00

  • EE72 Economic Burden of Long-Term Care (LTC) in Patients with Advanced Huntington's Disease (HD) and the Impact on Caregivers in North America: A Systematic Literature Review (SLR)

    Jun 1, 2024, 00:00

  • HPR30 Variation in per Beneficiary Prescription Utilization and Spending By Race/Ethnicity in Medicare and Medicaid Insurance Claims

    Jun 1, 2024, 00:00

  • RWD151 Knowledge Management Tool: A Large Language Model-Based Search Engine

    Jun 1, 2024, 00:00

  • MSR64 Using Large Language Models To Extract PD-L1 Testing Details From Electronic Health Records

    Jun 1, 2024, 00:00

  • AI and Machine Learning to Address Equity and Fairness in Healthcare

    Jun 1, 2024, 00:00

  • RWD105 The Clinical and Economic Burden of Woman with Endometriosis (EM)

    Jun 1, 2024, 00:00

  • HSD60 Self-Reported Pain Severity and Opioid Utilization in Adult Patients with Spine-Related Problems

    Jun 1, 2024, 00:00

  • CO144 Association of All-Cause and Cause-Specific Mortality with High-Risk NAFLD/NASH in US Adults, NHANES III (1988-1994) Linked to Mortality Data through 2019

    Jun 1, 2024, 00:00

  • PCR147 Breaking a Vicious Cycle: Including the Patient Perspective for Meaningful Psoriasis Severity Evaluation Towards Broader Recognition of Burden and Unmet Needs

    Jun 1, 2024, 00:00

  • MT4 The Trend, Outcomes, and Resources Utilization of Surgical Staplers Used in Patients Treated with Robotic Gastric Sleeve Procedures

    Jun 1, 2024, 00:00

  • EE426 Cost-Comparison Analysis of Non-Invasive Testing Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Veteran Population

    Jun 1, 2024, 00:00

  • HPR38 Estimating the Outcome Disparities in BIPOC and Economically-Disadvantages Patients With Systemic Lupus Erythematosus (SLE)

    Jun 1, 2024, 00:00

  • PCR98 Suboptimal Dosing and Discontinuation of Antifibrotic Agents in Patients with Idiopathic Pulmonary Fibrosis (IPF)

    Jun 1, 2024, 00:00

  • EE301 Economic Burden of Disease Recurrence in Elderly Patients With High-Risk Endometrial Cancer (HR-EC) Receiving Adjuvant Therapy (AT)

    Jun 1, 2024, 00:00

  • EPH59 A Systematic Review on the Health Equity Disparities in Lupus Treatment: Medicaid Vs. Private Payer Outcomes

    Jun 1, 2024, 00:00

  • EPH123 Incorporating Social Determinants of Health Into Transmission Modeling of COVID-19 Vaccine in the US: A Scoping Review

    Jun 1, 2024, 00:00

  • EE154 The Economic Burden of HER2+ Breast Cancer and the Epidemiological Economic Impact of Targeted Therapies in the Dominican Republic

    Jun 1, 2024, 00:00

  • PCR56 Are Limitations in Physical Function Relevant and Important Concepts To Assess in Patients on Antithrombotic Therapy for Cardiovascular Conditions?

    Jun 1, 2024, 00:00

  • MT44 Handheld Robotically Assisted Primary Unilateral Total Knee Arthroplasty (R-TKA) Demonstrates Lower Short-Term Costs and Length of Stay Compared to Conventional Instrumentation TKA (C-TKA)

    Jun 1, 2024, 00:00

  • EE14 Cost of Care Comparison of Elranatamab-bcmm and Teclistamab-cqyv in Adult Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

    Jun 1, 2024, 00:00

  • CO174 Baseline Characteristics of Patients with Asthma and Prior Oral Systemic Corticosteroid Use Initiating Dupilumab in a Real-World Registry (RAPID)

    Jun 1, 2024, 00:00

  • EPH178 Representing Thyroid Cancer Epidemiology in the US Over Time: A Microsimulation Modeling Approach Incorporating Temporal Differences in Thyroid Ultrasound Utilization by Sex and Age

    Jun 1, 2024, 00:00

  • RWD30 Ways To Minimize Data Quality Headaches in Migraine Research

    Jun 1, 2024, 00:00

  • EPH42 Evaluating the Public Health Impact of Dengue Vaccination in Indonesia: A Dynamic Transmission Modeling Assessment amidst Uncertainties in the Implementation Strategies

    Jun 1, 2024, 00:00

  • CO202 Relationship between Loss of Ambulation (LoA) and Timing of Pulmonary Outcomes Among Boys with Duchenne Muscular Dystrophy (DMD)

    Jun 1, 2024, 00:00

  • EE440 Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination in Adults Aged 50-59 Years With Cardiopulmonary Diseases in the United States

    Jun 1, 2024, 00:00

  • HSD92 Clinical Outcomes of Patients With Obesity in a US Employer-Funded Medical Weight Management Program: A Pilot Study

    Jun 1, 2024, 00:00

  • EE18 Burden of Illness for Adults With Chronic Inflammatory Demyelinating Polyneuropathy in the United States

    Jun 1, 2024, 00:00

  • EPH33 Trend of Mortality By Asthma in Colombia, 1998 - 2021

    Jun 1, 2024, 00:00

  • MSR63 Improving Efficiency in Analysis of Real-World Data with an Automated Machine Learning Tool

    Jun 1, 2024, 00:00

  • CO117 Factors Associated with Biologic Treatment De-Escalation in Patients with Crohn’s Disease

    Jun 1, 2024, 00:00

  • HSD112 Product Entry Sequence and Priority of Follow-on Drug Use: A Case Study of Second-Generation Antipsychotics with Long-Acting Injections

    Jun 1, 2024, 00:00

  • EE466 Implementing the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Sickle-Cell Disease: A Case Study

    Jun 1, 2024, 00:00

  • EE284 Cost-Effectiveness Analysis of Larotrectinib and Entrectinib for Adult Patients with NTRK Gene Fusion-Positive Breast Cancer

    Jun 1, 2024, 00:00

  • HSD44 Association of Penicillin Allergy Documentation and First-Line Penicillin Prescribing for Common Infections in Primary Healthcare Facilities in Beijing

    Jun 1, 2024, 00:00

  • EE168 Avoidable Costs in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated with Darolutamide

    Jun 1, 2024, 00:00

  • EE427 The Reduction in Medical and Care Costs for Diseases Associated with Being Bedridden in Rural Residents in Japan

    Jun 1, 2024, 00:00

  • EE462 Healthcare Utilization in Non-Alcoholic Steatohepatitis (NASH) Patients with Elevated Nafld Activity Score (NAS): Impact of Fibrosis Levels

    Jun 1, 2024, 00:00

  • EE107 Long-Term Cost-Effectiveness of iGlarLixi Versus IDegLira in Patients With Uncontrolled Type 2 Diabetes Treated With Basal Insulin or Oral Antidiabetic Drug in China

    Jun 1, 2024, 00:00

  • EE61 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Mexican Adults Population

    Jun 1, 2024, 00:00

  • EE488 Cost-Effectiveness Analysis of Faricimab and Others Treatment Schemes for Diabetic Macular Edema and Age-Related Macular Degeneration

    Jun 1, 2024, 00:00

  • EPH158 Using Data to Develop Precision Medicine Approaches to Public Health Initiatives

    Jun 1, 2024, 00:00

  • P30 Semi-Markov Model (sMM) Versus Trial-Level Surrogacy to Predict Overall Survival (OS) for Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) with Chemotherapy

    Jun 1, 2024, 00:00

  • RWD164 Evidence Gap Analysis of the Burden of Disease in Thyroid Eye Disease

    Jun 1, 2024, 00:00

  • HPR117 Emergency Room Utilization Among Multiple Sclerosis Patients Treated with Disease-Modifying Therapy in a Real-World Hybrid Claims Database

    Jun 1, 2024, 00:00

  • CO179 The Association Between Social Determinants of Health, COVID-19, and Incidence of De Novo Depression Following Traumatic Brain Injury

    Jun 1, 2024, 00:00

  • EE261 Costs and Outcomes Associated with COVID-19 Hospitalisation in the South African Public-Sector during the First-Wave

    Jun 1, 2024, 00:00

  • HSD30 Incidence of Platinum-Resistant, Stage III/IV Ovarian Cancer Patients in the US: A Mixed Source Estimation Approach

    Jun 1, 2024, 00:00

  • EPH89 Telehealth Utilization Among Children with Autism Spectrum Disorder in Employer-Sponsored Plans, 2019–2022

    Jun 1, 2024, 00:00

  • EE385 Changes in Direct Costs of Breast Cancer in Colombia From 2011 to 2022

    Jun 1, 2024, 00:00

  • Methodological Statistical Research

    Jun 1, 2024, 00:00

  • RWD187 The Use of a Large Epidemiological Surveillance Dataset (SIVEP-Gripe) for the Generation of Scientific Evidence in Brazil on COVID-19: A Literature Review

    Jun 1, 2024, 00:00

  • EPH7 Examination of Weight-Related Coding Practices in Administrative Claims: Implications for Future Analyses

    Jun 1, 2024, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • 6
  • 7
  • 8
  • 9
  • 10
  • »